The current stock price of AVXS is 217.83 null. In the past month the price increased by 3.35%. In the past year, price increased by 220.72%.
AveXis, Inc. is a gene therapy company which develops and commercializes treatments for neurological genetic diseases primarily in United States. The Company's product candidate consists of AVXS-101 which is in clinical trial for the treatment of spinal muscular atrophy Type 1, the genetic cause of infant mortality. AveXis, Inc. is headquartered in Bannockburn, Illinois.
AVEXIS INC
2275 HALF DAY ROAD SUIT 200
BANNOCKBURN IL 60015
CEO: Sean P. Nolan
Phone: 847-572-8280
AveXis, Inc. is a gene therapy company which develops and commercializes treatments for neurological genetic diseases primarily in United States. The Company's product candidate consists of AVXS-101 which is in clinical trial for the treatment of spinal muscular atrophy Type 1, the genetic cause of infant mortality. AveXis, Inc. is headquartered in Bannockburn, Illinois.
The current stock price of AVXS is 217.83 null. The price increased by 0.08% in the last trading session.
AVXS does not pay a dividend.
AVXS has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
AVEXIS INC (AVXS) has a market capitalization of 8.02B null. This makes AVXS a Mid Cap stock.
ChartMill assigns a technical rating of 10 / 10 to AVXS. When comparing the yearly performance of all stocks, AVXS is one of the better performing stocks in the market, outperforming 98.9% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to AVXS. AVXS has a great financial health rating, but its profitability evaluates not so good.
Over the last trailing twelve months AVXS reported a non-GAAP Earnings per Share(EPS) of -12.34. The EPS decreased by -98.37% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -61.51% | ||
| ROE | -72.09% | ||
| Debt/Equity | 0 |